Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Biotech Podcast: Shanghai Policy, US Draft Biosecure Bill, MNCs' China Strategy

Policy, Legislation And Business

Executive Summary

Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.

The Shanghai government is aiming to spur investment in three areas, including biotech, which is slated to receive additional funding from the major Chinese city.

What are some of the implications of the policy? (Also see "Shanghai's Latest Policy To Boost VC/PE Activities Amid Sector Downturn" - Scrip, 25 Jan, 2024.)

Meanwhile, a US House draft bill, Biosecure, is aimed at restricting Chinese gene sequencing and bio service providers from participating in US government contracts, causing WuXi Biologics' Hong Kong-listed shares to tumble.

What could be some of the long term impacts on the biotech sector? (Also see "US Draft Bill Highlights Perceived China Biotech Threat" - Scrip, 30 Jan, 2024.)

Scrip UK-based managing editor Kevin Grogan also joins Brian Yang to discuss his recent coverage of AstraZeneca PLC and Sanofi, in which executives of these multinationals shed light on their views of China, rising Chinese innovation and other challenges.



Scrip驻曼切斯特的编辑Kevin Grogan作为嘉宾加入讨论,他从最近采访阿斯利康商务拓展负责人Shaun Grady和赛诺菲首席执行官Paul Hudson分享了跨国药企对于中国市场的看法 (Also see "AstraZeneca Likes What Chinese Innovation Has To Offer" - Scrip, 6 Dec, 2023.) (Also see "Sanofi Chief Issues Warning To Innovation-Unfriendly EU" - Scrip, 2 Feb, 2024.),对于中国创新的机会的把握,和一些挑战的理解。





Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts